Clinical Guides
Kawasaki Disease
An India-adapted, evidence-mapped guide to recognising Kawasaki disease early, arranging cardiac assessment, and treating coronary inflammation without implying clinical review or publication approval.
MedNext Academy | 12 min read
Kawasaki Disease
An India-adapted, evidence-mapped guide to recognising Kawasaki disease early, arranging cardiac assessment, and treating coronary inflammation without implying clinical review or publication approval.
Summary
Kawasaki disease is an acute, predominantly childhood vasculitis whose important consequence is inflammation and structural injury in the coronary arteries. The illness cannot be confirmed by one swab, scan, antibody assay, or inflammatory marker. It is recognised from the pattern of sustained fever, mucocutaneous findings and the evolution of the illness, while actively excluding infections and inflammatory syndromes that need different treatment. Untreated disease can produce coronary dilatation or aneurysm; the American Heart Association describes coronary abnormalities in about one quarter of untreated children. That preventable risk explains why a child with a compatible fever should be assessed before every classical feature has appeared.
The bedside task is more precise than simply labelling fever with rash. Establish the first true fever day, document each principal feature, look for shock or myocarditis, obtain prompt paediatric and cardiology input, and arrange echocardiography without allowing a normal early study to dismiss a convincing presentation. IV immunoglobulin is time-sensitive acute therapy, with aspirin used in a protocol-directed anti-inflammatory and antiplatelet strategy. This review queue draft is authored by the MedNext Clinical Team for organisational review by the MedNext Clinical Team; it remains reviewed educational guide. It cannot replace a paediatric cardiology pathway, a current hospital protocol, or individual prescribing judgement.
How Common Is It?
Kawasaki disease is most often seen before five years of age, although older children and adolescents can be affected and are sometimes recognised late because clinicians expect a younger child. Incidence differs substantially between populations. The 2024 AHA statement gives United States rates of roughly 18 to 25 per 100,000 children under five and reports much higher rates in several north-east Asian countries. Those figures are useful for appreciating that geography influences observed burden; they are not a substitute for an Indian denominator.
India does not have a contemporary, nationwide, population-based surveillance system that establishes a single reliable incidence for Kawasaki disease. The Indian Academy of Pediatrics position paper reports increasing recognition across the country, but referral patterns, access to echocardiography, case definition, and overlap with infectious fever can all change what is counted. A learner should therefore avoid asserting a national prevalence from hospital series. In practice, the condition is uncommon compared with routine viral fever, yet its coronary implications make it disproportionately important. Fever lasting five days with conjunctival, oral, extremity, cutaneous, or cervical-node changes should trigger deliberate consideration even when the local clinic sees only occasional cases.
Risk Factors
The cause of Kawasaki disease remains unresolved. It is not established as a directly transmissible infection, and a parent should not be told that ordinary contact has caused the illness. Epidemiological and immunological observations suggest susceptibility in young children and variation by ancestry, family history, and environmental exposures, but these do not give a useful screening test. A prior uncomplicated viral illness neither proves nor rules out Kawasaki disease.
Risk in the acute encounter has two meanings. First, young infants can show fewer classical signs yet have important coronary involvement; unexplained fever in an infant warrants a lower threshold for specialist discussion. Second, once Kawasaki disease is suspected, the risk that matters most is coronary artery injury. Longer duration of untreated inflammation, abnormal baseline coronary dimensions, persistent fever after immunoglobulin, and clinical evidence of severe systemic inflammation may identify a child who needs close monitoring or intensified treatment according to a specialist protocol. Japanese risk scores have variable performance outside their development populations, so they must not be applied mechanically to Indian children. Record age, day of illness, inflammatory trajectory, cardiac function, coronary Z scores, and response to treatment rather than relying on a single imported score.
Diagnosis
History
Ask the caregiver to reconstruct fever day by day, including temperatures before antipyretics and any afebrile interval. The established clinical framework is fever for at least five days together with at least four of: bilateral non-purulent conjunctival injection; oral and lip changes; polymorphous rash; peripheral extremity changes; and cervical lymphadenopathy. Features need not emerge together. Red or cracked lips, a strawberry tongue, swollen hands or feet, and later periungual peeling are supportive, but peeling is often a later clue rather than a reason to delay assessment. Elicit gastrointestinal pain, vomiting, irritability, joint symptoms, reduced urine, respiratory symptoms, recent medicines, exposure history, and symptoms that suggest infection or MIS-C.
Examination
Measure full observations and perfusion first. Look carefully for limbal-sparing conjunctivitis, unilateral node enlargement, rash morphology, injection of the oropharynx without exudate, and tender oedema or erythema of palms and soles. Examine for gallop rhythm, murmur, hepatomegaly, shock, meningism, arthritis, and features discordant with Kawasaki disease such as vesicles, exudative pharyngitis, or discrete focal infection. Photographing evolving mucocutaneous findings with consent can help continuity across shifts.
Investigations
No laboratory test diagnoses Kawasaki disease. Obtain blood count, CRP or ESR, liver tests, albumin, electrolytes, urinalysis and cultures or pathogen testing directed by the differential. Sterile pyuria, thrombocytosis in the later phase, anaemia, raised transaminases and hypoalbuminaemia can support incomplete disease but are not specific. Echocardiography should evaluate ventricular function, valves, pericardium and both coronary arteries using body-surface-area-adjusted Z scores. In incomplete disease, prolonged fever with two or three principal features plus raised inflammation and supportive laboratory or echo evidence requires specialist-led assessment; a normal initial echocardiogram does not exclude it.
Differential Diagnosis
The differential is dictated by the fever pattern and the child’s physiology. Adenovirus can give fever, conjunctivitis and pharyngitis, but exudative throat disease and a positive appropriate virological test may shift probability; neither should automatically terminate a Kawasaki assessment when coronary features or the full phenotype remain persuasive. Scarlet fever has a toxin-mediated rash and pharyngitis, while measles, enterovirus, drug eruptions, staphylococcal or streptococcal toxin syndromes and cervical bacterial infection may create partial overlap. Culture and imaging choices should answer a plausible competing question rather than become a delay tactic.
MIS-C deserves explicit consideration in the appropriate post-SARS-CoV-2 setting because shock, abdominal symptoms, myocardial dysfunction and marked inflammation may be prominent. It can resemble Kawasaki disease but has its own evolving definitions, treatment pathways and cardiac surveillance requirements. Systemic juvenile idiopathic arthritis, polyarteritis nodosa and other inflammatory disorders are less common alternatives. Sepsis, toxic shock, meningococcal disease and myocarditis are immediately dangerous diagnoses: obtain resuscitation support and antimicrobials when indicated before diagnostic certainty is achieved. A structured note should state which alternative is being pursued, what evidence supports it, and when the child will be reassessed if fever or clinical signs evolve.
Management
A child with suspected Kawasaki disease should be discussed urgently with a paediatric team experienced in the condition and a paediatric cardiology service. Stabilise airway, breathing and circulation before focusing on diagnostic labels. Shock, arrhythmia, ventricular dysfunction, or significant abdominal or neurological involvement requires high-dependency or intensive-care capability. Baseline electrocardiography and echocardiography inform severity, but treatment should not be withheld while waiting for a technically difficult scan when the clinical diagnosis is strong.
Intravenous immunoglobulin is the cornerstone of acute treatment and is conventionally given as 2 g/kg in a single infusion under local protocol, ideally within the first ten illness days; late treatment can still be indicated when inflammation persists or coronary abnormalities are present. Monitor temperature, haemodynamics and infusion reactions. Persistent or recurrent fever after treatment needs specialist reassessment for alternative diagnoses, coronary change and rescue anti-inflammatory therapy. The choice among a second immunoglobulin infusion, corticosteroids or biologic therapy is a specialist decision that considers coronary risk, disease trajectory and local expertise.
Repeat echocardiography is central, not decorative. IAP guidance commonly supports studies at diagnosis, around two weeks and six to eight weeks, with more frequent imaging for abnormal coronaries or poor function. Long-term follow-up is determined by the maximum coronary Z-score category, regression or persistence of lesions, and thrombosis or stenosis risk. Give families a written follow-up plan, including who will communicate echo results and when urgent review is required.
Prescribing Information
Prescribing must be anchored to the current local paediatric and cardiology protocol. The commonly recommended acute IVIG dose is 2 g/kg as one infusion; product concentration, infusion rate, fluid load, renal risk, hypersensitivity precautions and observation requirements need verification against the hospital formulary. IVIG is not interchangeable with routine blood products, and live-vaccine timing after immunoglobulin must be reviewed with an immunisation service because passive antibodies can reduce response to certain live vaccines.
Aspirin has a specific role in Kawasaki disease that does not make it a routine fever medicine. IAP describes moderate- or high-dose aspirin during acute inflammation followed by low-dose antiplatelet therapy once afebrile, with dose selection and duration led by the treating unit and coronary findings. The family needs counselling about bleeding, vomiting, melena, tinnitus, accidental duplicate salicylate products and the plan if influenza or varicella is suspected. Aspirin should never be copied from this learning guide into an unsupervised prescription.
Children with large or giant aneurysms may require antiplatelet plus anticoagulant strategies, but agent choice, monitoring, peri-procedure planning and emergency chest-pain pathways belong to paediatric cardiology. Corticosteroids and biologics are not generic substitutes for IVIG; their indications and doses vary by risk profile. Document actual weight, illness day, product batch where relevant, allergies, cardiac measurements, vaccination advice and the named senior clinician responsible for the therapeutic decision.
When to Refer
Same-day referral to a paediatric unit is appropriate for a child with fever approaching or exceeding five days plus a convincing cluster of Kawasaki features, for an infant with unexplained prolonged fever, or for a child whose inflammatory results and partial phenotype suggest incomplete disease. Direct communication matters: tell the receiving clinician the exact fever day, features present and absent, observations, fluids, drugs already given, key laboratory values, and whether echocardiography has been arranged. Sending a child with a vague label of viral fever risks losing the time course that makes the diagnosis visible.
Urgent paediatric cardiology involvement is required at diagnosis or as soon as coronary abnormality, ventricular dysfunction, valvular regurgitation, arrhythmia or suspected myocarditis is identified. A normal first echo does not negate referral when the clinical diagnosis remains likely. Local access varies; if paediatric coronary imaging is unavailable, arrange transfer or remote specialist advice rather than treating a limited adult-focused study as definitive.
Emergency escalation is needed for shock, chest discomfort, syncope, signs of heart failure, rapidly worsening perfusion, altered consciousness, severe abdominal pain, gastrointestinal bleeding, or a child who deteriorates during an infusion. On discharge, referral is not complete until a named team owns serial echo follow-up and the caregivers understand whom to contact after recurrent fever, new symptoms, or missed appointments.
Red Flags
Kawasaki disease can present as a cardiovascular emergency rather than the textbook child with red eyes and peeling fingers. Immediate senior review is indicated for hypotension, tachycardia out of proportion to fever, cool extremities, prolonged capillary refill, oliguria, rising lactate, respiratory distress, gallop rhythm, hepatomegaly, or an abnormal ECG. These findings raise concern for Kawasaki disease shock syndrome, myocarditis, ventricular impairment or a competing diagnosis such as sepsis or toxic shock. Manage physiology first and obtain intensive-care support.
Neurological irritability is common but reduced consciousness, seizures, focal deficit, neck stiffness or severe persistent headache demand broader evaluation. Marked abdominal pain, vomiting, jaundice, bleeding, hydrops-type findings or disproportionate anaemia can signal severe systemic involvement or another disease. Do not dismiss these as incidental because the rash seems familiar.
From a coronary perspective, a change in echocardiographic dimensions, impaired left ventricular function, pericardial effusion, mitral regurgitation, or very high inflammatory burden should prompt rapid specialist review. In a child with known aneurysm, chest pain, pallor, collapse, unexplained breathlessness or vomiting can be an ischaemic presentation and requires emergency assessment. Clear documentation of time, observation trends and escalation decisions reduces the risk that progressive cardiac disease is hidden across handovers.
Indian Clinical Context
The IAP position paper is the principal India-specific source in this draft and is valuable because it addresses diagnosis, echocardiography and treatment in Indian practice. It was published in 2020, however, so it should be read with its date in mind. The newer 2024 AHA statement contributes updated evidence and risk stratification but is a North American scientific statement, not an Indian formulary or referral standard. Neither source supplies a contemporary national Indian incidence estimate.
India’s practical challenge is that prolonged febrile illness often first presents in settings with limited paediatric echocardiography and a broad infectious differential. A clinician should not let limited imaging access convert a reasonable diagnostic concern into inaction. Instead, record the phenotype, obtain initial tests that help distinguish infection and inflammation, call a paediatric referral centre, and arrange safe transport if coronary imaging and IVIG administration are unavailable locally. Cost, travel and product availability may affect timing; those barriers require active escalation, not undocumented delay.
NMC 2024 establishes the educational framework but does not itself provide a Kawasaki drug schedule. Local antimicrobial policies, blood-product safety rules, immunisation services and cardiology follow-up arrangements must govern care. This draft explicitly remains reviewed: it is a learning resource awaiting independent clinical review, not a claim that the MedNext Clinical Team has approved a patient-care protocol.
NMC Competency Mapping
Kawasaki disease is best used to integrate NMC 2024 paediatric competencies rather than memorise an isolated eponym. The learner should take and interpret a focused history of prolonged fever, rash, conjunctival and oral changes; perform a safe child examination; recognise a time-critical inflammatory disorder; and explain why coronary assessment changes outcome. These are clinical reasoning and communication tasks as well as knowledge tasks.
At a know-how level, students should distinguish a compatible complete presentation from incomplete disease, formulate a ranked differential that includes infection and MIS-C, select baseline investigations with a stated purpose, and interpret a coronary artery report using the specialist’s Z-score framework. At a show-how level, they should present a concise referral call that includes illness day, haemodynamic status, mucocutaneous features, relevant negative findings and whether IVIG access is available. They should also counsel a caregiver about serial echocardiography, aspirin precautions and the importance of returning for review.
The map is intentionally descriptive because the 2024 NMC curriculum is a broad competency compendium rather than a condition-specific Kawasaki protocol. Assessment can use a fever-and-rash case, a paediatric observation chart, an echo report interpretation exercise and an oral handover station. Learners must state when supervision is required; they should not independently prescribe IVIG, aspirin or anticoagulation from a teaching case.
Key Exam Pearls for NEET PG
Kawasaki disease is a medium-vessel vasculitis and the leading acquired heart disease cause in children in high-income settings. The classic examination construct is fever for at least five days plus four of five principal clinical features: non-purulent bilateral conjunctivitis, oral mucosal changes, polymorphous rash, extremity changes and cervical lymphadenopathy. Desquamation is usually a later clue. There is no single confirmatory laboratory test.
The key complication is coronary artery dilatation or aneurysm. Remember that absence of all classical signs does not make the diagnosis impossible: incomplete Kawasaki disease is particularly important in infants and requires a combination of inflammation, supportive laboratory findings and echocardiography within a specialist algorithm. Platelet count may rise in the subacute stage, so early thrombocytosis is not required.
For management questions, IVIG 2 g/kg is the standard acute anchor and aspirin has disease-specific anti-inflammatory then antiplatelet use under protocol. Echocardiography is obtained early and repeated; a normal baseline scan cannot exclude evolving coronary disease. Separate Kawasaki disease from scarlet fever, adenovirus, toxic shock and MIS-C by the whole clinical and investigation pattern, not by one rash descriptor. Imported risk scores and exact aspirin dose bands should never be selected without knowing the guideline and patient context.
Frequently Asked Questions
Why can Kawasaki disease be diagnosed before every classic sign is visible?
The phenotype develops over time, and some children, especially infants, never display all five principal features. Persistent fever with compatible findings, raised inflammation and supportive laboratory or cardiac evidence may meet an incomplete-disease pathway. Waiting for peeling or a complete checklist can lose the period in which IVIG most effectively reduces coronary injury. A paediatric specialist should direct that assessment.
Does a normal first echocardiogram rule out coronary involvement in Kawasaki disease?
No. Early coronary dimensions can be normal despite a credible clinical presentation, and abnormalities can evolve later in the acute or subacute period. Echocardiography evaluates more than coronaries, including ventricular function, valves and pericardium, and needs interpretation with Z scores by an experienced service. Serial imaging and clinical review, rather than one reassuring study, determine follow-up.
Can caregivers give over-the-counter aspirin for suspected Kawasaki disease at home?
No. Aspirin use in Kawasaki disease is protocol-directed and requires a confirmed weight, illness assessment, bleeding-risk review, counselling and a plan for influenza or varicella exposure. It is not ordinary antipyretic therapy for a febrile child. A suspected case needs urgent medical assessment; caregivers should instead record temperatures, fluids, urine output, evolving signs and medicines already taken.
What are the important India and source-age limitations of this Kawasaki guide?
The IAP position paper is India-specific but dates from 2020; the AHA statement is newer, published in 2024, but represents North American scientific guidance. India lacks a contemporary nationwide incidence figure in the sources used here, and NMC 2024 is a curriculum source rather than a prescribing guide. Local cardiology, blood-product, vaccination and transfer procedures therefore remain decisive.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic